Disclosing Potential Key Genes, Therapeutic Targets and Agents for Non-Small Cell Lung Cancer: Evidence from Integrative Bioinformatics Analysis
文献类型：期刊论文
| 作者 | Mosharaf, Md Parvez1,5; Reza, Md Selim2,5; Gov, Esra3; Mahumud, Rashidul Alam4; Mollah, Md Nurul Haque5 |
| 刊名 | VACCINES
 |
| 出版日期 | 2022-05-01 |
| 卷号 | 10期号:5页码:20 |
| 关键词 | non-small cell lung cancer gene expression profiles molecular signatures therapeutic targets and agents integrated bioinformatics approaches |
| DOI | 10.3390/vaccines10050771 |
| 英文摘要 | Non-small-cell lung cancer (NSCLC) is considered as one of the malignant cancers that causes premature death. The present study aimed to identify a few potential novel genes highlighting their functions, pathways, and regulators for diagnosis, prognosis, and therapies of NSCLC by using the integrated bioinformatics approaches. At first, we picked out 1943 DEGs between NSCLC and control samples by using the statistical LIMMA approach. Then we selected 11 DEGs (CDK1, EGFR, F Upsilon N, UBC, M Upsilon C, CCNB1, FOS, RHOB, CDC6, CDC20, and CHEK1) as the hub-DEGs (potential key genes) by the protein-protein interaction network analysis of DEGs. The DEGs and hub-DEGs regulatory network analysis commonly revealed four transcription factors (FOXC1, GATA2, Upsilon Upsilon 1, and NFIC) and five miRNAs (miR-335-5p, miR-26b-5p, miR-92a-3p, miR-155-5p, and miR-16-5p) as the key transcriptional and post-transcriptional regulators of DEGs as well as hub-DEGs. We also disclosed the pathogenetic processes of NSCLC by investigating the biological processes, molecular function, cellular components, and KEGG pathways of DEGs. The multivariate survival probability curves based on the expression of hub-DEGs in the SurvExpress web-tool and database showed the significant differences between the low- and high-risk groups, which indicates strong prognostic power of hub-DEGs. Then, we explored top-ranked 5-hub-DEGs-guided repurposable drugs based on the Connectivity Map (CMap) database. Out of the selected drugs, we validated six FDA-approved launched drugs (Dinaciclib, Afatinib, Icotinib, Bosutinib, Dasatinib, and TWS-119) by molecular docking interaction analysis with the respective target proteins for the treatment against NSCLC. The detected therapeutic targets and repurposable drugs require further attention by experimental studies to establish them as potential biomarkers for precision medicine in NSCLC treatment. |
| WOS研究方向 | Immunology ; Research & Experimental Medicine |
| 语种 | 英语 |
| WOS记录号 | WOS:000803470300001 |
| 出版者 | MDPI |
| 源URL | [http://119.78.100.204/handle/2XEOYT63/19576]  |
| 专题 | 中国科学院计算技术研究所期刊论文_英文 |
| 通讯作者 | Mollah, Md Nurul Haque |
| 作者单位 | 1.Univ Southern Queensland, Fac Business Educ Law & Arts, Sch Commerce, Toowoomba, Qld 4350, Australia 2.Chinese Acad Sci, Ctr High Performance Comp, Joint Engn Res Ctr Hlth Big Data Intelligent Anal, Shenzhen Inst Adv Technol, Shenzhen 518055, Peoples R China 3.Adana AlparslanTurkes Sci & Technol Univ, Fac Engn, Dept Bioengn, TR-01250 Adana, Turkey 4.Univ Sydney, Fac Med & Hlth, NHMRC Clin Trials Ctr, Camperdown, NSW 2006, Australia 5.Univ Rajshahi, Dept Stat, Bioinformat Lab, Rajshahi 6205, Bangladesh |
| 推荐引用方式 GB/T 7714 | Mosharaf, Md Parvez,Reza, Md Selim,Gov, Esra,et al. Disclosing Potential Key Genes, Therapeutic Targets and Agents for Non-Small Cell Lung Cancer: Evidence from Integrative Bioinformatics Analysis[J]. VACCINES,2022,10(5):20. |
| APA | Mosharaf, Md Parvez,Reza, Md Selim,Gov, Esra,Mahumud, Rashidul Alam,&Mollah, Md Nurul Haque.(2022).Disclosing Potential Key Genes, Therapeutic Targets and Agents for Non-Small Cell Lung Cancer: Evidence from Integrative Bioinformatics Analysis.VACCINES,10(5),20. |
| MLA | Mosharaf, Md Parvez,et al."Disclosing Potential Key Genes, Therapeutic Targets and Agents for Non-Small Cell Lung Cancer: Evidence from Integrative Bioinformatics Analysis".VACCINES 10.5(2022):20. |
入库方式： OAI收割
来源：计算技术研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。